{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:54:55Z","timestamp":1793037295150,"version":"4.5.0"},"reference-count":260,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-NS108968-01"],"award-info":[{"award-number":["R01-NS108968-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011495","name":"Massachusetts Life Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011495","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jconrel.2022.10.018","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T07:11:14Z","timestamp":1666163474000},"page":"121-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies"],"prefix":"10.1016","volume":"352","author":[{"given":"Smrithi","family":"Padmakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha N.","family":"Parayath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Bleier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor M.","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.10.018_bb0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrd837","article-title":"Nucleic-acid therapeutics: basic principles and recent applications","volume":"1","author":"Opalinska","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0015","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.3390\/cancers13195002","article-title":"Nucleic acid drugs\u2014current status, issues, and expectations for exosomes","volume":"13","author":"Yamada","year":"2021","journal-title":"Cancers."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bcp.12987","article-title":"Therapeutic nucleic acids: current clinical status","volume":"82","author":"Sridharan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/life9030059","article-title":"Synthetic approaches for nucleic acid delivery: choosing the right carriers","volume":"9","author":"Ni","year":"2019","journal-title":"Life."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.579062","article-title":"Genome editing for CNS disorders","volume":"14","author":"Duarte","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"The Lancet Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","article-title":"Molecular pathology of neurodegenerative diseases: principles and practice","volume":"72","author":"Kovacs","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1566523220999200817164907","article-title":"Targeted delivery for neurodegenerative disorders using gene therapy vectors: gene next therapeutic goals","volume":"21","author":"Singh","year":"2021","journal-title":"CGT."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2007.56","article-title":"Protein misfolding and neurodegeneration","volume":"65","author":"Soto","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0055","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17425247.2020.1727443","article-title":"Delivery of neurotrophic factors in the treatment of age-related chronic neurodegenerative diseases","volume":"17","author":"Padmakumar","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2217\/nmt-2019-0006","article-title":"A good marker does not mean a good target for clinical trials in Alzheimer\u2019s disease: the amyloid hypothesis questioned","volume":"9","author":"Modrego","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0070","first-page":"358","article-title":"Blots on a field?","volume":"377","author":"Piller","year":"2022","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0075","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2016.00108","article-title":"Non-viral nucleic acid delivery strategies to the central nervous system","volume":"9","author":"Tan","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0085","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","article-title":"Advances in the design of (nano) formulations for delivery of antisense oligonucleotides and small interfering RNA: Focus on the central nervous system","volume":"18","author":"Mendonca","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0090","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/17425247.2016.1188802","article-title":"Current status of non-viral gene therapy for CNS disorders","volume":"13","author":"Jayant","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0095","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0192623318803867","article-title":"Considerations for preclinical safety assessment of adeno-associated virus gene therapy products","volume":"46","author":"Assaf","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.580179","article-title":"Gene therapy for neurodegenerative diseases: slowing down the ticking clock","volume":"14","author":"Martier","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/mz400418j","article-title":"Advancing polymeric delivery systems amidst a nucleic acid therapy renaissance","volume":"2","author":"Burke","year":"2013","journal-title":"ACS Macro Lett."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1208\/s12248-009-9143-y","article-title":"Nonviral gene delivery: principle, limitations, and recent progress","volume":"11","author":"Al-Dosari","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0115","series-title":"Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers","volume":"9","author":"Durymanov","year":"2018"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg1577","article-title":"Towards safe, non-viral therapeutic gene expression in humans","volume":"6","author":"Glover","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.643681","article-title":"Nucleic acid\u2013based therapeutics in orphan neurological disorders: recent developments","volume":"8","author":"Khorkova","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425240902758188","article-title":"Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases","volume":"6","author":"Barchet","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0135","series-title":"The Cerebral Circulation, Colloquium Series on Integrated Systems Physiology: From Molecule to Function","first-page":"1","volume":"1","author":"Cipolla","year":"2009"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0145","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain","volume":"11","author":"Pardridge","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"11","key":"10.1016\/j.jconrel.2022.10.018_bb0155","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0160","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.msec.2016.04.011","article-title":"Nanomaterials for delivery of nucleic acid to the central nervous system (CNS)","volume":"70","author":"Wang","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.biotechadv.2015.02.004","article-title":"BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS","volume":"33","author":"Peluffo","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.3784","article-title":"Oligonucleotide therapies for disorders of the nervous system","volume":"35","author":"Khorkova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0175","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2021.01.027","article-title":"Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain","volume":"331","author":"Padmakumar","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119657","article-title":"Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases","volume":"230","author":"Samaridou","year":"2020","journal-title":"Biomaterials."},{"issue":"6","key":"10.1016\/j.jconrel.2022.10.018_bb0185","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","article-title":"Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes","volume":"17","author":"Dhaliwal","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0190","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","article-title":"Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood\u2013brain barrier and knock down genes in the rodent CNS","volume":"39","author":"Nagata","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0195","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1039\/D1NR06939J","article-title":"Overcoming barriers in non-viral gene delivery for neurological applications","volume":"14","author":"Tasset","year":"2022","journal-title":"Nanoscale."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12035-021-02555-y","article-title":"Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases","volume":"59","author":"Parambi","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.pbr.2016.11.003","article-title":"Ex vivo gene therapy for the treatment of neurological disorders","volume":"230","author":"Gowing","year":"2017","journal-title":"Prog. Brain Res."},{"issue":"3","key":"10.1016\/j.jconrel.2022.10.018_bb0210","first-page":"265","article-title":"Immunoisolation cell therapy for CNS diseases","volume":"18","author":"Emerich","year":"2001","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2018.09.011","article-title":"Stem cell therapy for neurological disorders: a focus on aging","volume":"126","author":"Nguyen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0220","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/sctm.19-0430","article-title":"Mesenchymal stem cells as a multimodal treatment for nervous system diseases","volume":"9","author":"Badyra","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/sctm.19-0202","article-title":"Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?","volume":"9","author":"Kabat","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0230","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/ijms21093103","article-title":"Neural stem cell transplantation for neurodegenerative diseases","volume":"21","author":"De Gioia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0235","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hgtb.2013.026","article-title":"Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, rapamycin-dependent gene switch","volume":"24","author":"Mart\u00edn-Saavedra","year":"2013","journal-title":"Hum Gene Ther. Methods."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0240","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/mt.2015.8","article-title":"Controlled striatal DOPA production from a gene delivery system in a rodent model of Parkinson\u2019s disease","volume":"23","author":"Cederfj\u00e4ll","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0245","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1007\/s00253-015-6965-7","article-title":"Lost signature: progress and failures in in vivo tracking of implanted stem cells","volume":"99","author":"Von der Haar","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0250","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0255","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0260","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0265","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1021\/acs.langmuir.2c00200","article-title":"Nanoparticle properties influence transendothelial migration of monocytes","volume":"38","author":"Nahal","year":"2022","journal-title":"Langmuir."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41434-018-0003-1","article-title":"Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR\/Cas9","volume":"25","author":"Stephens","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0275","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41587-020-00756-9","article-title":"Safety questions for AAV gene therapy","volume":"39","author":"Venditti","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0280","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0285","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0167-7799(02)00042-2","article-title":"Latest development in viral vectors for gene therapy","volume":"21","author":"Lundstrom","year":"2003","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0290","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0295","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/156652308786847996","article-title":"Applications of lentiviral vectors for biology and gene therapy of neurological disorders","volume":"8","author":"Lundberg","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0300","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0305","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1021\/mp400467x","article-title":"Overcoming nonviral gene delivery barriers: perspective and future","volume":"10","author":"Jones","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: Recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0315","first-page":"88","article-title":"Genomics to gene therapy in neurology","volume":"18","author":"Renthal","year":"2019","journal-title":"Pract. Neurol."},{"issue":"12","key":"10.1016\/j.jconrel.2022.10.018_bb0320","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/alz.12342","article-title":"Knowledge gaps in Alzheimer\u2019s disease immune biomarker research","volume":"17","author":"Morgan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0325","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7571-6_1","article-title":"Neurotrophic factors: an overview","volume":"1727","author":"Skaper","year":"2018","journal-title":"Methods Mol Biol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.10.018_bb0335","first-page":"53","article-title":"Neurotrophic factors and Parkinson\u2019s disease","volume":"7","author":"Bhardwaj","year":"2018","journal-title":"Clin. Investig."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0340","first-page":"32","article-title":"Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?","volume":"4","author":"Henriques","year":"2010","journal-title":"Front Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0345","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/pharmaceutics13020206","article-title":"Lipid nanoparticles as delivery systems for RNA-based vaccines","volume":"13","author":"Aldosari","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0350","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","article-title":"Nerve growth factor: early studies and recent clinical trials","volume":"16","author":"Rocco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnagi.2021.645583","article-title":"Failure of glial cell-line derived neurotrophic factor (GDNF) in clinical trials orchestrated by reduced NR4A2 (NURR1) transcription factor in Parkinson\u2019s Disease, a systematic review","volume":"13","author":"Kambey","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0360","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/biomedicines10051143","article-title":"Brain-derived neurotropic factor in neurodegenerative disorders","volume":"10","author":"Ibrahim","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0365","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fnins.2018.00222","article-title":"Ultrasound-triggered effects of the microbubbles coupled to GDNF plasmid-loaded PEGylated liposomes in a rat model of Parkinson\u2019s Disease","volume":"12","author":"Yue","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0370","first-page":"20","article-title":"Intranasal delivery of hGDNF plasmid DNA nanoparticles results in long-term and widespread transfection of perivascular cells in rat brain, Nanomedicine: Nanotechnology","volume":"16","author":"Aly","year":"2019","journal-title":"Biol. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0375","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.actbio.2018.06.014","article-title":"In vitro efficacy of a gene-activated nerve guidance conduit incorporating non-viral PEI-pDNA nanoparticles carrying genes encoding for NGF, GDNF and c-Jun","volume":"75","author":"Lackington","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0380","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12035-018-1109-6","article-title":"Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the Rat 6-hydroxydopamine model of Parkinson\u2019s Disease","volume":"56","author":"Aly","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0385","doi-asserted-by":"crossref","first-page":"1900727","DOI":"10.1002\/adma.201900727","article-title":"Efficient delivery of nerve growth factors to the central nervous system for neural regeneration","volume":"31","author":"Xu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0390","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1474-4422(02)00006-6","article-title":"Growth-factor gene therapy for neurodegenerative disorders","volume":"1","author":"Tuszynski","year":"2002","journal-title":"The Lancet Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0395","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0400","first-page":"560","article-title":"RNA interference technology","author":"Xu","year":"2019","journal-title":"Compr. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0405","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0410","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/ng1105-1163","article-title":"RNAi the natural way","volume":"37","author":"Cullen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0415","doi-asserted-by":"crossref","first-page":"1903637","DOI":"10.1002\/adma.201903637","article-title":"Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"issue":"4","key":"10.1016\/j.jconrel.2022.10.018_bb0420","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4155\/tde.12.22","article-title":"Delivery of siRNA into the blood\u2013brain barrier: recent advances and future perspective","volume":"3","author":"Kuwahara","year":"2012","journal-title":"Therapeutic Deliv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0425","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/cancers12051197","article-title":"Long non-coding RNA HOTAIR in breast cancer therapy","volume":"12","author":"Cantile","year":"2020","journal-title":"Cancers."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0430","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-1-4939-8651-4_26","article-title":"Pre-mRNA splicing modulation by antisense oligonucleotides","volume":"1828","author":"Singh","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0435","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418776932","article-title":"Antisense oligonucleotides in neurological disorders","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0445","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/bab.2028","article-title":"Antisense oligonucleotide (AS-ODN) technology: principle, mechanism and challenges","volume":"68","author":"Gheibi-Hayat","year":"2021","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-4939-1221-6_9","article-title":"Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects","volume":"825","author":"Rigo","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0455","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0460","doi-asserted-by":"crossref","first-page":"eaay2069","DOI":"10.1126\/scitranslmed.aay2069","article-title":"Wrangling RNA: antisense oligonucleotides for neurological disorders","volume":"11","author":"Talbot","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0465","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.8380941","article-title":"Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides","volume":"259","author":"Wahlestedt","year":"1993","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0470","series-title":"Intrathecal Delivery of Antisense Oligonucleotide Therapeutics: Transport Mechanisms and Factors Influencing Distribution in the Central Nervous System","author":"Wilken-Resman","year":"2019"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0475","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature02329","article-title":"The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis","volume":"428","author":"Garkavtsev","year":"2004","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0480","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.3892\/ol.2017.6618","article-title":"Expression of ING4 is negatively correlated with cellular proliferation and microvessel density in human glioma","volume":"14","author":"Shao","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0485","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.biomaterials.2014.10.034","article-title":"Enhanced blood\u2013brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system","volume":"37","author":"Yao","year":"2015","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0490","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.ymthe.2017.04.023","article-title":"Antitumoral cascade-targeting ligand for IL-6 receptor-mediated gene delivery to glioma","volume":"25","author":"Wang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0495","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/adhm.201500563","article-title":"Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma","volume":"4","author":"Wang","year":"2015","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0500","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00268-002-4053-5","article-title":"Current progress in suicide gene therapy for cancer","volume":"26","author":"Yazawa","year":"2002","journal-title":"World J. Surg."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0505","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1021\/mp4006003","article-title":"Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma-specific gene therapy","volume":"11","author":"Kim","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0510","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3389\/fphar.2019.00724","article-title":"Gene therapy tools for brain diseases","volume":"10","author":"Ingusci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0515","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4155\/tde.13.44","article-title":"Noncovalently associated cell-penetrating peptides for gene delivery applications","volume":"4","author":"Alhakamy","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0520","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11095-007-9439-5","article-title":"Nonviral approaches for neuronal delivery of nucleic acids","volume":"25","author":"Bergen","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0525","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ymthe.2003.09.011","article-title":"Deoxyribonuclease II is a lysosomal barrier to transfection","volume":"8","author":"Pinto-Gonz\u00e1lez Howell","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0530","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3109\/1061186X.2013.830310","article-title":"Strategies on the nuclear-targeted delivery of genes","volume":"21","author":"Yao","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0535","series-title":"Novel Gene Therapy Approaches","article-title":"Extracellular and intracellular barriers to non-viral gene transfer","author":"F","year":"2013"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0540","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s11095-010-0364-7","article-title":"Barriers to non-viral vector-mediated gene delivery in the nervous system","volume":"28","author":"P\u00e9rez-Mart\u00ednez","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0545","article-title":"In vivo targeted gene delivery to peripheral neurons mediated by neurotropic poly(ethylene imine)-based nanoparticles","volume":"2675","author":"Pego","year":"2016","journal-title":"IJN."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0550","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/acs.molpharmaceut.0c00755","article-title":"Synthetic monopartite peptide that enables the nuclear import of genes delivered by the neurotensin-polyplex vector","volume":"17","author":"Lopez-Salas","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0555","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/jgm.1062","article-title":"Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine)","volume":"9","author":"Park","year":"2007","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0560","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.biomaterials.2006.11.015","article-title":"Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons","volume":"28","author":"Zeng","year":"2007","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00080","article-title":"Non-viral gene therapy that targets motor neurons in vivo","volume":"7","author":"Rogers","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0570","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12929-015-0166-7","article-title":"Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson\u2019s disease","volume":"22","author":"Hernandez-Chan","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0575","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1006\/mthe.2001.0324","article-title":"Transgene expression in the brain stem effected by intramuscular injection of polyethylenimine\/DNA complexes","volume":"3","author":"Wang","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0580","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1566523024605609","article-title":"Intracellular barriers to non-viral gene transfer","volume":"2","author":"Lechardeur","year":"2002","journal-title":"CGT."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0585","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","article-title":"The endosomal escape of nanoparticles: toward more efficient cellular delivery","volume":"30","author":"Smith","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0590","doi-asserted-by":"crossref","first-page":"44826","DOI":"10.1074\/jbc.M308643200","article-title":"Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes","volume":"278","author":"Sonawane","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0595","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/mt.2012.185","article-title":"The Possible \u201cProton Sponge \u201d Effect of Polyethylenimine (PEI) Does Not Include Change in Lysosomal pH","volume":"21","author":"Benjaminsen","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0600","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/ph5111177","article-title":"Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: Strategies and Challenges","volume":"5","author":"Erazo-Oliveras","year":"2012","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0605","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.3390\/ijms22169092","article-title":"Peptide-assisted nucleic acid delivery systems on the rise","volume":"22","author":"Tarvirdipour","year":"2021","journal-title":"IJMS."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.03.398","article-title":"Human-derived fusogenic peptides for the intracellular delivery of proteins","volume":"255","author":"Sudo","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0615","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.gene.2012.05.053","article-title":"Arginine-rich cell-penetrating peptides deliver gene into living human cells","volume":"505","author":"Liu","year":"2012","journal-title":"Gene."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0620","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy","volume":"11","author":"Gregory","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0625","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52012","article-title":"A molecular view on the escape of lipoplexed DNA from the endosome","volume":"9","author":"Bruininks","year":"2020","journal-title":"ELife."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0630","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.281.5373.78","article-title":"An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery","volume":"281","author":"Koltover","year":"1998","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0635","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1074\/jbc.275.3.1625","article-title":"Size-dependent DNA Mobility in Cytoplasm and Nucleus","volume":"275","author":"Lukacs","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0640","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170995","article-title":"Peptides mediating DNA transport on microtubules and their impact on non-viral gene transfer efficiency","volume":"37","author":"Midoux","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0645","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymthe.2005.10.004","article-title":"Intracellular trafficking of plasmids during transfection is mediated by microtubules","volume":"13","author":"Vaughan","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0650","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/hum.2005.16.200","article-title":"Enhanced intracellular mobility and nuclear accumulation of DNA plasmids associated with a karyophilic protein","volume":"16","author":"Mesika","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0655","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.gt.3302534","article-title":"Nuclear entry of nonviral vectors","volume":"12","author":"Dean","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0660","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jgm.1010","article-title":"Cell cycle dependent transcription, a determinant factor of heterogeneity in cationic lipid-mediated transgene expression","volume":"9","author":"Akita","year":"2007","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0665","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2010.01.019","article-title":"Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells","volume":"389","author":"Zou","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0670","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1073\/pnas.96.1.91","article-title":"Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus","volume":"96","author":"Zanta","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0675","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.gt.3302534","article-title":"Nuclear entry of nonviral vectors","volume":"12","author":"Dean","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0680","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1476-5381.2009.00288.x","article-title":"Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers","volume":"157","author":"Midoux","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0685","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/pharmaceutics14010165","article-title":"Non-viral delivery of RNA gene therapy to the central nervous system","volume":"14","author":"Hauck","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0690","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.chembiol.2004.06.006","article-title":"Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells","volume":"11","author":"Chiu","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0695","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.conb.2006.05.001","article-title":"Importin-mediated nuclear transport in neurons","volume":"16","author":"Otis","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0700","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1523\/JNEUROSCI.3314-09.2009","article-title":"Activity-dependent anchoring of importin at the synapse involves regulated binding to the cytoplasmic tail of the NR1-1a subunit of the NMDA receptor","volume":"29","author":"Jeffrey","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0705","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2015.00033","article-title":"An importin code in neuronal transport from synapse-to-nucleus?","volume":"8","author":"Lever","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0710","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1073\/pnas.1515526113","article-title":"Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration","volume":"113","author":"Sellers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0715","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mt.2013.237","article-title":"Long-distance axonal transport of AAV9 Is driven by dynein and Kinesin-2 and Is trafficked in a highly motile Rab7-positive compartment","volume":"22","author":"Castle","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0720","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijpharm.2011.07.007","article-title":"A cytoplasm-sensitive peptide vector cross-linked with dynein light chain association sequence (DLCAS) enhances gene expression","volume":"419","author":"Tanaka","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0725","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.685802","article-title":"Toward development of neuron specific transduction after systemic delivery of viral vectors","volume":"12","author":"Finneran","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0730","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/1061186X.2012.655247","article-title":"Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression","volume":"20","author":"Hsu","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0735","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/104303404322959498","article-title":"Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter","volume":"15","author":"Zhang","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0740","series-title":"Vector Design and Considerations for CNS Applications","first-page":"9","author":"Gray","year":"2011"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0745","doi-asserted-by":"crossref","first-page":"15055","DOI":"10.1038\/mtm.2015.55","article-title":"AAV9-mediated central nervous system\u2013targeted gene delivery via cisterna magna route in mice","volume":"3","author":"Lukashchuk","year":"2016","journal-title":"Mol. Ther. Methods Clin. Develop."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0750","doi-asserted-by":"crossref","first-page":"16081","DOI":"10.1038\/mtm.2016.81","article-title":"Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9","volume":"3","author":"Dashkoff","year":"2016","journal-title":"Mol. Ther. Methods Clin. Develop."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0755","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jps.10286","article-title":"Barriers to nonviral gene delivery","volume":"92","author":"Wiethoff","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0760","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1359-6446(02)02243-2","article-title":"Targeting tumors with non-viral gene delivery systems","volume":"7","author":"Ogris","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0765","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ymthe.2003.11.012","article-title":"Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors","volume":"9","author":"Zhao","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0770","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/1547691X.2021.1902432","article-title":"Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung","volume":"18","author":"de Braganca","year":"2021","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0775","doi-asserted-by":"crossref","first-page":"eabd6889","DOI":"10.1126\/sciadv.abd6889","article-title":"BBB pathophysiology\u2013independent delivery of siRNA in traumatic brain injury","volume":"7","author":"Li","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0780","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","article-title":"Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease","volume":"279","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0785","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/pharmaceutics12121216","article-title":"Current Status and challenges associated with CNS-targeted gene delivery across the BBB","volume":"12","author":"Kimura","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0790","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","article-title":"Recent advances in the development of gene delivery systems","volume":"23","author":"Sung","year":"2019","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0795","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.gt.3301983","article-title":"Progress and prospects: naked DNA gene transfer and therapy","volume":"10","author":"Herweijer","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0800","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.gt.3302838","article-title":"Gene therapy progress and prospects: non-viral gene therapy by systemic delivery","volume":"13","author":"Li","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0805","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/exnr.2000.7584","article-title":"In vivo transfection of lamprey brain neurons by gene gun delivery of DNA","volume":"167","author":"Zhang","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0810","doi-asserted-by":"crossref","first-page":"29817","DOI":"10.1038\/srep29817","article-title":"Rapid and efficient gene delivery into the adult mouse brain via focal electroporation","volume":"6","author":"Nomura","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0815","doi-asserted-by":"crossref","first-page":"10388","DOI":"10.1074\/jbc.275.14.10388","article-title":"Up-regulation of protein-disulfide isomerase in response to hypoxia\/brain ischemia and its protective effect against apoptotic cell death*","volume":"275","author":"Tanaka","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0820","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.01.069","article-title":"Up-regulation of anterior cingulate cortex NR2B receptors contributes to visceral pain responses in rats","volume":"136","author":"Fan","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0825","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-213X-7-107","article-title":"Electroporation of cDNA\/Morpholinos to targeted areas of embryonic CNS in Xenopus","volume":"7","author":"Falk","year":"2007","journal-title":"BMC Dev. Biol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0830","doi-asserted-by":"crossref","first-page":"H629","DOI":"10.1152\/ajpheart.00126.2012","article-title":"Nonviral gene therapy targeting cardiovascular system","volume":"303","author":"Su","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0835","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pneurobio.2010.10.001","article-title":"In vivo electroporation of the central nervous system: A non-viral approach for targeted gene delivery","volume":"92","author":"De Vry","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0840","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00177540","article-title":"Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial","volume":"10","author":"Guthkelch","year":"1991","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0845","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mrm.20118","article-title":"500-element ultrasound phased array system for noninvasive focal surgery of the brain: a preliminary rabbit study with ex vivo human skulls","volume":"52","author":"Hynynen","year":"2004","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0850","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.06.023","article-title":"Magnetic-resonance imaging for kinetic analysis of permeability changes during focused ultrasound-induced blood\u2013brain barrier opening and brain drug delivery","volume":"192","author":"Chai","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0860","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1038\/srep19579","article-title":"Noninvasive, targeted and non-viral ultrasound-mediated GDNF-plasmid delivery for treatment of Parkinson\u2019s Disease","volume":"6","author":"Fan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.06.010","article-title":"Focused ultrasound-induced blood-brain barrier opening for non-viral, non-invasive, and targeted gene delivery","volume":"212","author":"Lin","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0870","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.brs.2019.04.011","article-title":"Focused ultrasound-induced blood brain-barrier opening enhanced vascular permeability for GDNF delivery in Huntington\u2019s disease mouse model","volume":"12","author":"Lin","year":"2019","journal-title":"Brain Stimulat."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0875","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.addr.2008.03.005","article-title":"Microbubbles in ultrasound-triggered drug and gene delivery","volume":"60","author":"Hernot","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0880","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.gt.3302925","article-title":"Gene therapy progress and prospects: ultrasound for gene transfer","volume":"14","author":"Newman","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0885","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2016.02.003","article-title":"Microbubbles and ultrasound increase intraventricular polyplex gene transfer to the brain","volume":"231","author":"Tan","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0890","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1006\/mthe.2002.0577","article-title":"Fetal gene transfer by intrauterine injection with microbubble-enhanced ultrasound","volume":"5","author":"Endoh","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0895","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081245","article-title":"Ultrasound-mediated blood-brain barrier opening improves whole brain gene delivery in mice","volume":"13","author":"Felix","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0900","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.biomaterials.2009.09.085","article-title":"Gene transfer using self-assembled ternary complexes of cationic magnetic nanoparticles, plasmid DNA and cell-penetrating Tat peptide","volume":"31","author":"Song","year":"2010","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0905","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.nano.2015.01.012","article-title":"Enduring high-efficiency in vivo transfection of neurons with non-viral magnetoparticles in the rat visual cortex for optogenetic applications","volume":"11","author":"Soto-S\u00e1nchez","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0910","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.gt.3302720","article-title":"Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery","volume":"13","author":"Dobson","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0915","doi-asserted-by":"crossref","DOI":"10.1227\/01.NEU.0000097715.11966.8E","article-title":"Mechanisms of disease: the blood-brain barrier","volume":"54","author":"Neuwelt","year":"2004","journal-title":"Neurosurgery."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0920","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1749-6632.1986.tb27155.x","article-title":"Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier","volume":"481","author":"Rapoport","year":"1986","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0925","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12248-008-9018-7","article-title":"Recent advances in blood-brain barrier disruption as a CNS delivery strategy","volume":"10","author":"Bellavance","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0930","first-page":"5278","article-title":"Pharmacology and neurotoxicity of cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification","volume":"43","author":"Neuwelt","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0935","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1023\/A:1016248701505","article-title":"The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake","volume":"12","author":"Kawabata","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0940","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7150\/thno.6914","article-title":"Current progress in gene delivery technology based on chemical methods and nano-carriers","volume":"4","author":"Jin","year":"2014","journal-title":"Theranostics."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0945","first-page":"183","article-title":"Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration","volume":"3","author":"Hwang","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0950","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1556-276X-9-252","article-title":"A sight on the current nanoparticle-based gene delivery vectors","volume":"9","author":"Dizaj","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0955","doi-asserted-by":"crossref","first-page":"105032","DOI":"10.1016\/j.chemphyslip.2020.105032","article-title":"Cationic lipids for gene delivery: many players, one goal","volume":"235","author":"Ponti","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0960","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0965","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jgm.659","article-title":"Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels","volume":"7","author":"Hassani","year":"2005","journal-title":"The J. Gene Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0970","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1039\/C4CC09871D","article-title":"Hyperosmotic polydixylitol for crossing the blood brain barrier and efficient nucleic acid delivery","volume":"51","author":"Garg","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0975","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.2147\/IJN.S140734","article-title":"Preparation, characterization, and transfection efficiency of low molecular weight polyethylenimine-based nanoparticles for delivery of the plasmid encoding CD200 gene","volume":"12","author":"Nouri","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.10.018_bb0980","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.biomaterials.2011.03.047","article-title":"A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA","volume":"32","author":"Hwang","year":"2011","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0985","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/bm401906p","article-title":"RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain","volume":"15","author":"Gao","year":"2014","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0990","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biomaterials.2014.10.068","article-title":"Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer\u2019s disease","volume":"38","author":"Park","year":"2015","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb0995","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.ymthe.2018.08.005","article-title":"Transvascular delivery of hydrophobically modified siRNAs: gene silencing in the rat brain upon disruption of the blood-brain barrier","volume":"26","author":"Godinho","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1000","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.nano.2015.12.374","article-title":"Intranasal brain delivery of cationic nanoemulsion-encapsulated TNF\u03b1 siRNA in prevention of experimental neuroinflammation","volume":"12","author":"Yadav","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1005","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1021\/bc200406n","article-title":"In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles","volume":"22","author":"Jin","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1010","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.1073\/pnas.0504926102","article-title":"Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain","volume":"102","author":"Bharali Dhruba","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1015","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","article-title":"Neuroprotective effect of gold nanoparticles composites in Parkinson\u2019s disease model","volume":"14","author":"Hu","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1020","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1073\/pnas.1100930108","article-title":"Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing","volume":"108","author":"Al-Jamal","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2015.01.051","article-title":"Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation","volume":"481","author":"Danhier","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1030","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1016\/j.biomaterials.2009.08.049","article-title":"Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer","volume":"30","author":"Ke","year":"2009","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1035","doi-asserted-by":"crossref","first-page":"119657","DOI":"10.1016\/j.biomaterials.2019.119657","article-title":"Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases","volume":"230","author":"Samaridou","year":"2020","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1040","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","article-title":"Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles","volume":"34","author":"Kanazawa","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1045","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/hmg\/ddr217","article-title":"Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum","volume":"20","author":"Du","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1050","article-title":"Non viral vectors in gene therapy- an overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J. Clin. Diagn. Res. JCDR"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2011.11.012","article-title":"Intracellular partitioning of cell organelles and extraneous nanoparticles during mitosis","volume":"64","author":"Symens","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1060","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1523\/JNEUROSCI.0183-10.2010","article-title":"Transfection techniques for neuronal cells","volume":"30","author":"Karra","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1065","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/mp300470d","article-title":"Polyplex exposure inhibits cell cycle, increases inflammatory response, and can cause protein expression without cell division","volume":"10","author":"Matz","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1075","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1016\/j.ymthe.2021.09.010","article-title":"Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary","volume":"29","author":"Morris","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna","volume":"28","author":"Taghian","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41434-021-00223-3","article-title":"Use of CRISPR\/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice","volume":"28","author":"Torregrosa","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1090","article-title":"Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound","volume":"8","author":"Hsu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1227\/00006123-198812000-00001","article-title":"Use of implantable pumps for central nervous system drug infusions to treat neurological disease","volume":"23","author":"Harbaugh","year":"1988","journal-title":"Neurosurgery."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/hum.2017.026","article-title":"Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","article-title":"Convection-enhanced delivery","volume":"14","author":"Mehta","year":"2017","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3171\/jns.1999.90.2.0315","article-title":"Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time","volume":"90","author":"Chen","year":"1999","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/neuonc\/nor051","article-title":"Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump","volume":"13","author":"Sonabend","year":"2011","journal-title":"Neuro-Oncology."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/17425240903540205","article-title":"Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics","volume":"7","author":"Soderquist","year":"2010","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1135","first-page":"1","article-title":"Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model","author":"D\u2019Amico","year":"2019","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2004.06.020","article-title":"Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience\/biomaterial interface","volume":"190","author":"Whittlesey","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1145","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/nnm-2021-0311","article-title":"Nasal delivery of nanotherapeutics for CNS diseases: challenges and opportunities","volume":"16","author":"D\u2019Souza","year":"2021","journal-title":"Nanomedicine (London, England)"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1150","doi-asserted-by":"crossref","first-page":"869269","DOI":"10.1155\/2014\/869269","article-title":"Drug delivery systems, CNS protection, and the blood brain barrier","volume":"2014","author":"Upadhyay","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1160","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1227\/NEU.0000000000001016","article-title":"Heterotopic mucosal grafting enables the delivery of therapeutic neuropeptides across the blood brain barrier","volume":"78","author":"Bleier","year":"2016","journal-title":"Neurosurgery."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208122","article-title":"Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting","volume":"13","author":"Pawar","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1170","doi-asserted-by":"crossref","first-page":"120989","DOI":"10.1016\/j.biomaterials.2021.120989","article-title":"Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach","volume":"276","author":"Padmakumar","year":"2021","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1175","series-title":"Recent Patents on Drug Delivery & Formulation","first-page":"25","article-title":"Recent patents review on intranasal administration for CNS drug delivery","volume":"2","author":"Jogani","year":"2008"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1180","first-page":"1102","article-title":"Preliminary study on brain-targeted drug delivery via inner ear","volume":"42","author":"Chen","year":"2007","journal-title":"Yao xue xue bao = Acta pharmaceutica Sinica"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1185","first-page":"37","article-title":"Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer\u2019s disease: a new route of administration","volume":"27","author":"Lehrer","year":"2019","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.10.018_bb1190","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/15476286.2021.2021650","article-title":"RNA-based therapeutics for neurological diseases","volume":"19","author":"Anthony","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1195","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1200","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1205","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aba4624","article-title":"Antisense oligonucleotides for neurodegeneration","volume":"367","author":"Leavitt","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1210","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1215","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.omtn.2022.04.007","article-title":"Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD","volume":"28","author":"Liu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/brain\/awf012","article-title":"Brain function in Duchenne muscular dystrophy","volume":"125","author":"Anderson","year":"2002","journal-title":"Brain."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with duchenne muscular dystrophy amenable to Exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Therap."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1240","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1245","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1250","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours","volume":"2","author":"Lee","year":"2018","journal-title":"Nat Biomed Eng."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1255","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1260","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1265","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-018-07971-8","article-title":"CRISPR\/Cas9 editing of APP C-terminus attenuates \u03b2-cleavage and promotes \u03b1-cleavage","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1275","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.omtn.2018.03.007","article-title":"CRISPR\/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer\u2019s Disease","volume":"11","author":"Gy\u00f6rgy","year":"2018","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1280","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In vivo neuronal gene editing via CRISPR\u2013Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer\u2019s disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1285","article-title":"CRISPR\/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson\u2019s disease","author":"Yoon","year":"2020","journal-title":"Genetics"},{"key":"10.1016\/j.jconrel.2022.10.018_bb1290","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1295","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.3390\/ijms22179241","article-title":"Understanding the potential of genome editing in Parkinson\u2019s Disease","volume":"22","author":"Arango","year":"2021","journal-title":"IJMS."},{"key":"10.1016\/j.jconrel.2022.10.018_bb1300","doi-asserted-by":"crossref","first-page":"602970","DOI":"10.3389\/fgeed.2020.602970","article-title":"Methodologies and challenges for CRISPR\/Cas9 mediated genome editing of the mammalian brain","volume":"2","author":"Nishizono","year":"2020","journal-title":"Front. Genome Ed."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922006885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922006885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:31:26Z","timestamp":1759163486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922006885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":260,"alternative-id":["S0168365922006885"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleic acid therapies for CNS diseases: Pathophysiology, targets, barriers, and delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}